Why famed short-seller Andrew Left says he's betting against Palantir: 'It's become so absurd'

Renowned short-seller Andrew Left of Citron Research has initiated a short position against Palantir (PLTR), arguing its valuation is "unjustifiable" despite a colossal 144% stock surge. Left highlights PLTR's extreme 80x price-to-sales and 290x forward price-to-earnings ratios, asserting the stock could fall by two-thirds even if compared to Nvidia's 2023 multiples. This move by a prominent short-seller, currently facing SEC charges, signals a significant bearish challenge to Palantir's recent AI-driven rally and retail investor popularity.

Analysis

Renowned short-seller Andrew Left of Citron Research has publicly disclosed a short position against Palantir (PLTR), challenging the company's colossal 144% stock surge in 2025. The core of Left's bearish thesis is an extreme valuation, which he deems unjustifiable despite the company's strong second-quarter earnings and its popularity as an AI play. He highlights Palantir's price-to-sales ratio of approximately 80x and a forward price-to-earnings multiple of 290x, metrics he describes as absurd. To underscore this point, Left argues that even if Palantir were assigned Nvidia's 2023 multiples, the stock could still face a two-thirds decline. The analysis also points to Palantir's significant following among retail investors as a negative indicator, framing the stock's rally as a "high-multiple, hype-driven narrative." However, investors should note the accompanying context that Left is currently facing SEC charges for market manipulation and securities fraud, which adds a layer of complexity when evaluating the credibility of this bearish call.

Key Decisions for Investors

• Investors with long positions in Palantir should critically re-evaluate the stock's valuation risk, as its high multiples make it highly susceptible to sentiment shifts and market corrections.
• Traders considering a short position based on this thesis must weigh the compelling valuation argument against the significant risk of a short squeeze, given the stock's strong momentum and substantial retail investor interest.
• All parties should monitor Palantir's upcoming earnings for fundamental growth that could justify its premium valuation, while also tracking developments in Andrew Left's SEC legal case, as its outcome could influence the market's perception of Citron's research.